DVA · 10-Q · 2026Q2 · Full report

Operating Expense Trends

DAVITA INC. · 2026-08-04 · Importance 49 · Surprise 32 · Contradicted

U.S. dialysis patient-care costs increased 3.4% year over year to $3.974 billion for the first six months of 2026, and patient-care cost per treatment increased 3.2% to $278.74. The increase was primarily caused by higher compensation and wage rates, insurance costs, and health-benefit expense. U.S. dialysis general and administrative expense increased 9.4% year over year to $650.7 million because of higher IT-related costs and compensation, partly offset by the absence of 2025 cybersecurity-related costs. Depreciation and amortization declined 3.8% to $301.6 million because certain assets became fully depreciated.

Key facts

• As of June 30, 2026, total estimated but unrecognized stock-based compensation expense: $195,359 to be recognized over weighted average remaining period of 1.4 years source
• Other income (loss), net for the six months ended June 30, 2026: $12,773 (compared to ($40,400) in 2025) source
• U.S. dialysis patient care costs for the three months ended June 30, 2026: $2,004,694 thousand source
• U.S. dialysis patient care costs for six months ended June 30, 2026: $3,973,750 thousand source
• Stock-settled restricted and performance stock units granted during six months ended June 30, 2026 had aggregate grant-date fair value of $116,627, and stock-settled stock appreciation rights granted had aggregate grant-date fair value of $5,460 source
• Patient care costs for the six months ended June 30, 2026: $4,734,258 source
• General and administrative expense for the six months ended June 30, 2026: $845,372 source
• U.S. dialysis general and administrative expenses for the three months ended June 30, 2026: $330,892 thousand source

Impact estimates